Drug Therapy

>

Latest News

Pivotal data for lumasiran in PH1 published in NEJM
Pivotal data for lumasiran in PH1 published in NEJM

April 1st 2021

The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.

Nedosiran explored in primary hyperoxaluria type 3
Nedosiran explored in primary hyperoxaluria type 3

February 26th 2021

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

February 9th 2021

FDA approves androgen inhibitor for metastatic PCa

September 12th 2012

Blood test could guide treatment for kidney cancer

August 29th 2012

More News

© 2024 MJH Life Sciences

All rights reserved.